Gene therapy has moved from experimental research into commercial treatment, with the FDA approving therapies for conditions including sickle cell disease, β-thalassemia, hemophilia and retinal disorders. In July 2026, the FDA expanded CASGEVY to patients aged 2 years and older with certain forms of sickle cell disease and transfusion-dependent β-thalassemia.
Approval, however, does not guarantee commercial scale. Gene therapies can require specialized treatment centres, complex manufacturing and logistics, extended monitoring and substantial upfront costs.
For manufacturers and investors, the relevant question is whether a market has enough eligible patients, treatment capacity and payer support to convert clinical potential into sustainable treatment volume.
Patient Volume Is Only the First Filter
The overall disease population provides a starting point, but the commercially addressable population is considerably narrower.
For sickle cell disease, more than 100,000 people in the US are affected, with approximately 50–60% enrolled in Medicaid. CMS estimates that hospitalizations and other healthcare associated with the disease cost nearly $3 billion annually.
A market assessment therefore needs to distinguish between:
- Patients meeting the approved indication
- Disease severity and treatment eligibility
- Age and clinical criteria
- Previous treatment history
- Geographic distribution
- Payer coverage
- Patients able to access an authorized treatment centre
This produces a more realistic estimate of the population that can be treated.
Infrastructure Can Determine the Speed of Adoption
Gene therapy requires infrastructure that conventional medicines generally do not.
Patients may need specialist evaluation, conditioning, cell collection, treatment administration and extended follow-up. For autologous therapies, patient-specific material also needs to move through a controlled collection, manufacturing and delivery process.
Treatment-centre capacity should therefore be assessed alongside patient demand:
- Centre availability: Number and location of qualified facilities
- Clinical capability: Specialists, equipment and supporting services
- Capacity: Patients that can be treated within a defined period
- Referral networks: Ability to identify and direct eligible patients
- Logistics: Collection, processing, transportation and chain-of-custody requirements
A market can have substantial eligible demand but limited near-term commercial potential if treatment infrastructure cannot accommodate that population.
The Economics Are Part of Market Access
Gene therapies can involve multi-million-dollar upfront costs. CMS lists the initial prices of CASGEVY and LYFGENIA for sickle-cell disease at $2.2 million and $3.1 million per patient, respectively.
The payment structure creates a challenge for payers because costs are concentrated around treatment, while potential benefits may accrue over many years.
CMS’s Cell and Gene Therapy Access Model addresses this through outcomes-based agreements between manufacturers and participating state Medicaid programs. As of 2026, 34 Medicaid programs are participating.
Where Nexdigm Can Test the Commercial Case
Nexdigm’s gene therapy market feasibility study brings patient demand, infrastructure and market access into a single assessment.
The analysis can examine:
- Patient opportunity: Eligible and geographically addressable populations
- Treatment infrastructure: Qualified centres, specialist capacity and referral networks
- Manufacturing and logistics: Production, processing and delivery requirements
- Pricing and reimbursement: Payer coverage, affordability and payment models
- Competition: Approved and emerging therapies
- Market access: Regulatory requirements and practical barriers to treatment
This helps companies determine whether a market is ready for commercialization or whether infrastructure, reimbursement or patient-access constraints need to be addressed first.
How Nexdigm Evaluates Gene Therapy Market Feasibility
- 01 | Quantify the Treatable Population
Go beyond disease prevalence to identify patients who meet the therapy’s indication, clinical criteria and treatment requirements, establishing the realistic addressable population. - 02 | Map Treatment Capacity
Assess authorized treatment centres, specialist availability, geographic coverage and patient throughput to determine whether existing infrastructure can support projected demand. - 03 | Test Delivery Feasibility
Evaluate manufacturing capacity, patient-specific logistics, processing timelines, chain-of-custody requirements and treatment infrastructure to identify constraints on scale-up. - 04 | Assess the Reimbursement Equation
Examine pricing, payer coverage, reimbursement mechanisms and alternative payment models to determine whether the therapy can be financed at the expected treatment volume. - 05 | Establish Market Attractiveness
Bring patient potential, treatment capacity, delivery requirements, access and competitive conditions together to identify markets where commercial expansion is feasible and where further investment is required.
Nexdigm’s Case: From Patient Potential to Commercial Feasibility
A gene-therapy developer evaluated 4 markets before expanding its treatment network. Nexdigm assessed eligible patients, treatment-centre capacity, payer coverage and logistics requirements, identifying 2 markets for near-term expansion and infrastructure priorities for the remaining markets.
Gene therapy’s commercial potential depends on the interaction between eligible patients, treatment capacity and affordability. Nexdigm helps pharmaceutical and biotechnology companies assess these conditions market by market, identify constraints and prioritize expansion opportunities before committing significant capital.
To take the next step, simply visit our Request a Consultation page and share your requirements with us.
Harsh Mittal
+91-8422857704
[email protected]